Imago BioSciences to Expand Clinical Trial of IMG-7829 for MF Patients
Presented at the 24th Congress of the European Hematology Association (EHA), Imago BioSciences, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 1/2a clinical trial of a lysine-specific demethylase (LSD1) inhibitor, IMG-7289. Imago decided to expand the study into a Phase 2b trial and is evaluating clinical investigations in additional myeloid diseases.
“IMG-7289 has shown tremendous promise to be a meaningful treatment option for myelofibrosis patients, and these data support our clinical program,” said Hugh Young Rienhoff, Jr. M.D., chief executive officer of Imago BioSciences. “These data, particularly the strong safety and efficacy signals, have informed our Phase 2b dosing strategy and encourage us to explore additional indications in myeloproliferative diseases."